Zhao Zeng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Zhao Zeng has a total of 77 co-authors. Here are the top co-authors by number of shared publications:
Suning Chen
National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology The First Affiliated Hospital of Soochow University Suzhou Jiangsu Province China
5 shared publicationsQiongyu Lu
Cyrus Tang Hematology Center, Soochow University, Suzhou, China
4 shared publicationsDepei Wu
National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology The First Affiliated Hospital of Soochow University Suzhou China
2 shared publicationsPeng Ke
National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China
2 shared publications- Xiebing Bao
National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China
2 shared publications Biao Wang
Department of Hematology The Third Affiliated Hospital of Soochow University (The First People's Hospital of Changzhou) Changzhou China
1 shared publication
Latest Publications
- 12 November 2026
- Published by Wiley in International Journal of Cancer
Exploring Efficacy and Predictors of Response to Venetoclax and Hypomethylating Agents in Newly Diagnosed Acute Myeloid Leukemia: A Real‐World Study
This retrospective study aimed to identify molecular predictors of treatment response and survival in 207 newly diagnosed acute myeloid leukemia (AML) patients treated with Venetoclax combined with hypomethylating agents (VEN‐HMAs). After one treatment course, the composite complete remission (CR/CRi) rate was 69.6% (144/207), with 70.5% (93/132) of responders achieving minimal residual disease (MRD) negativity. According to the 2017 ELN risk stratification, the CR/CRi rates in the favorable‐, intermediate‐, and high‐risk groups were 77.2%, 64.0%, and 66.6%, respectively. For treatment response, RUNX1‐RUNX1T1 , FLT3‐ITD , and TP53 mutations independently predicted unfavorable to VEN‐HMAs therapy. Multivariable analysis identified NRAS and PTPN11 mutations as independent adverse prognostic factors for overall survival, while achievement of CR/CRi after the first treatment course and receiving hematopoietic stem cell transplantation (HSCT) were favorable predictors. Based on molecular status, patients were stratified into three prognostic groups. The median OS was 9.5 months in the TP53 ‐mutant (low‐benefit) group and 21 months in the medium‐benefit group ( TP53 wild‐type with FLT3‐ITD or K / NRAS mutations). The high‐benefit group (wild‐type TP53 , no FLT3‐ITD , and wild‐type K / NRAS ) had a significantly superior OS (not reached) compared to the others ( p < 0.001), while OS between the medium‐ and low‐benefit groups was comparable ( p = 0.096). VEN‐HMAs therapy is associated with high response rates in this real‐world cohort, though treatment response varies substantially by molecular profile. A comprehensive understanding of these influencing factors and the development of refined risk stratification systems require further investigation.
- 12 November 2026
- Published by Wiley in International Journal of Cancer
Exploring Efficacy and Predictors of Response to Venetoclax and Hypomethylating Agents in Newly Diagnosed Acute Myeloid Leukemia: A Real‐World Study
This retrospective study aimed to identify molecular predictors of treatment response and survival in 207 newly diagnosed acute myeloid leukemia (AML) patients treated with Venetoclax combined with hypomethylating agents (VEN‐HMAs). After one treatment course, the composite complete remission (CR/CRi) rate was 69.6% (144/207), with 70.5% (93/132) of responders achieving minimal residual disease (MRD) negativity. According to the 2017 ELN risk stratification, the CR/CRi rates in the favorable‐, intermediate‐, and high‐risk groups were 77.2%, 64.0%, and 66.6%, respectively. For treatment response, RUNX1‐RUNX1T1 , FLT3‐ITD , and TP53 mutations independently predicted unfavorable to VEN‐HMAs therapy. Multivariable analysis identified NRAS and PTPN11 mutations as independent adverse prognostic factors for overall survival, while achievement of CR/CRi after the first treatment course and receiving hematopoietic stem cell transplantation (HSCT) were favorable predictors. Based on molecular status, patients were stratified into three prognostic groups. The median OS was 9.5 months in the TP53 ‐mutant (low‐benefit) group and 21 months in the medium‐benefit group ( TP53 wild‐type with FLT3‐ITD or K / NRAS mutations). The high‐benefit group (wild‐type TP53 , no FLT3‐ITD , and wild‐type K / NRAS ) had a significantly superior OS (not reached) compared to the others ( p < 0.001), while OS between the medium‐ and low‐benefit groups was comparable ( p = 0.096). VEN‐HMAs therapy is associated with high response rates in this real‐world cohort, though treatment response varies substantially by molecular profile. A comprehensive understanding of these influencing factors and the development of refined risk stratification systems require further investigation.
- 19 September 2026
- Published by Wiley in British Journal of Haematology
- Vol. 209 (5) , 2103-2116
Hyperdiploid multiple myeloma: A heterogeneous entity requiring refined risk stratification—Insights from chromosome count and cytogenetic abnormalities
Summary: Hyperdiploidy (HRD) is the most common genetic subtype in multiple myeloma (MM) but with significant prognostic heterogeneity. In this integrated Single Nucleotide Polymorphism (SNP‐array) and Fluorescence In Situ Hybridization (FISH) analysis of 694 newly diagnosed Chinese MM patients, a modal chromosome count >49 predicted superior overall survival (OS, p = 0.0062) and progression‐free survival (PFS, p = 0.00037), outperforming other metrics. Gain of chromosome 3 was favourable for OS ( p = 0.0024) and PFS ( p = 0.00078). Notably, HRD improved OS in patients with isolated 1q21 + ( p = 0.011) but not in those harbouring high‐risk abnormalities (t(4;14), t(14;16), 17p − or 1p32 − ). The prognostic value of modal count was cytogenetic abnormality (CA)‐dependent: in HRD without high‐risk CAs, >49 conferred better OS ( p = 0.01) and PFS ( p = 0.001); in isolated 1q21 + , a favourable trend was observed; but no discrimination in other high‐risk CAs. Autologous haematopoietic stem cell transplantation (AHSCT) significantly improved OS ( p = 0.014) and showed a PFS trend ( p = 0.062) only in HRD patients without high‐risk CAs and with >49 chromosomes. In conclusion, modal chromosome count >49 and chromosome 3 gain are robust favourable markers in HRD. HRD provides survival benefit in isolated 1q21 + . FISH‐based detection of trisomy 3 may offer a rapid, economical alternative for risk assessment of HRD. AHSCT benefit is restricted to low‐risk HRD with higher ploidy.
- 19 September 2026
- Published by Wiley in British Journal of Haematology
- Vol. 209 (5) , 2103-2116
Hyperdiploid multiple myeloma: A heterogeneous entity requiring refined risk stratification—Insights from chromosome count and cytogenetic abnormalities
Summary: Hyperdiploidy (HRD) is the most common genetic subtype in multiple myeloma (MM) but with significant prognostic heterogeneity. In this integrated Single Nucleotide Polymorphism (SNP‐array) and Fluorescence In Situ Hybridization (FISH) analysis of 694 newly diagnosed Chinese MM patients, a modal chromosome count >49 predicted superior overall survival (OS, p = 0.0062) and progression‐free survival (PFS, p = 0.00037), outperforming other metrics. Gain of chromosome 3 was favourable for OS ( p = 0.0024) and PFS ( p = 0.00078). Notably, HRD improved OS in patients with isolated 1q21 + ( p = 0.011) but not in those harbouring high‐risk abnormalities (t(4;14), t(14;16), 17p − or 1p32 − ). The prognostic value of modal count was cytogenetic abnormality (CA)‐dependent: in HRD without high‐risk CAs, >49 conferred better OS ( p = 0.01) and PFS ( p = 0.001); in isolated 1q21 + , a favourable trend was observed; but no discrimination in other high‐risk CAs. Autologous haematopoietic stem cell transplantation (AHSCT) significantly improved OS ( p = 0.014) and showed a PFS trend ( p = 0.062) only in HRD patients without high‐risk CAs and with >49 chromosomes. In conclusion, modal chromosome count >49 and chromosome 3 gain are robust favourable markers in HRD. HRD provides survival benefit in isolated 1q21 + . FISH‐based detection of trisomy 3 may offer a rapid, economical alternative for risk assessment of HRD. AHSCT benefit is restricted to low‐risk HRD with higher ploidy.
- Open Access
- 7 November 2025
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 15, 1701989
Integrated CIRCLE-seq with RNA-seq to decipher the quantity, localization, and functional features of eccDNA in AML
Background: Extrachromosomal circular DNA (eccDNA) plays critical roles in cancer, yet its landscape in acute myeloid leukemia (AML) remains unexplored. Methods: We used CIRCLE-seq and RNA-seq to characterize eccDNA in 12 AML patients and 4 healthy controls. Results: AML cells showed significantly increased eccDNA counts and gene involvement versus healthy controls, with distinct size peaks at 202 and 368 bp. eccDNAs localized non-randomly to chromosomes 1, 2, and 10–19, enriching near transcription start sites and regulatory regions. Functional analysis revealed activation of oncogenic pathways (e.g., MAPK, ErbB signaling) in AML-associated eccDNA. Integrative analysis identified 570 genes upregulated at both the eccDNA and mRNA levels, including myeloid leukemia-related genes (e.g., FLT3 , RUNX1 , and CD33 ) and oncogenes. Prognostic analysis showed that high expression of these genes correlated with poor outcomes in AML. Conclusions: This study unveils the eccDNA landscape in AML by direct CIRCLE-seq, linking its accumulation to transcriptional dysregulation and leukemogenesis, and highlights eccDNA as a potential biomarker and therapeutic target.
- 7 November 2025
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 15, 1701989
Open AccessIntegrated CIRCLE-seq with RNA-seq to decipher the quantity, localization, and functional features of eccDNA in AML
Background: Extrachromosomal circular DNA (eccDNA) plays critical roles in cancer, yet its landscape in acute myeloid leukemia (AML) remains unexplored. Methods: We used CIRCLE-seq and RNA-seq to characterize eccDNA in 12 AML patients and 4 healthy controls. Results: AML cells showed significantly increased eccDNA counts and gene involvement versus healthy controls, with distinct size peaks at 202 and 368 bp. eccDNAs localized non-randomly to chromosomes 1, 2, and 10–19, enriching near transcription start sites and regulatory regions. Functional analysis revealed activation of oncogenic pathways (e.g., MAPK, ErbB signaling) in AML-associated eccDNA. Integrative analysis identified 570 genes upregulated at both the eccDNA and mRNA levels, including myeloid leukemia-related genes (e.g., FLT3 , RUNX1 , and CD33 ) and oncogenes. Prognostic analysis showed that high expression of these genes correlated with poor outcomes in AML. Conclusions: This study unveils the eccDNA landscape in AML by direct CIRCLE-seq, linking its accumulation to transcriptional dysregulation and leukemogenesis, and highlights eccDNA as a potential biomarker and therapeutic target.
- 7 February 2024
- Published by Wiley in British Journal of Haematology
- Vol. 204 (4) , 1402-1413
Risk factors and survival analysis of human leukocyte antigen loss in relapsed acute myeloid leukaemia/myelodysplastic syndrome patients after allogeneic haematopoietic stem cell transplantation
Summary: To investigate the clinical characteristics and risk factors of specific human leukocyte antigen loss (HLA loss) in relapsed acute myeloid leukaemia (AML)/myelodysplastic syndrome (MDS) patients after allogeneic haematopoietic stem cell transplantation (allo‐HSCT), and compare the responses of patients with HLA loss relapse with those without HLA loss (non‐HLA loss) to different treatment regimens. Clinical data of traceable patients with AML/MDS after myeloablative allo‐HSCT in our centre between January 2010 and June 2021, who experienced disease relapse after the transplantation, were collected. The patients were divided into the HLA loss relapse group and the non‐HLA loss relapsed group based on HLA loss gene test findings by next‐generation sequencing. The patients' median overall survival (OS) after the relapse were compared, and univariate and multivariate analyses were performed using the Kaplan–Meier survival curve and Cox proportional hazard model to explore the responses to different treatments after relapse. A total of 2359 patients were selected. Retrospective HLA gene loss gene detection was performed for the deoxyribonucleic acid in 179 relapsed patients, including 47 patients in the HLA loss group (27.2%), 126 patients in the non‐HLA loss group (72.8%) and 6 patients were excluded due to a lack of confirmed results. There was no significant statistical difference in the baseline characteristics of patients between the two groups, but as to transplantation‐related characteristics, the donor–recipient relationship and HLA mismatched loci were statistically different between the two groups (both p < 0.001). Multivariate Cox analysis showed that more HLA mismatched loci ≥3 (HR = 3.66; 95% CI: 1.61–8.31; p = 0.002), time (≤6 months) from HSCT to relapse (HR = 7.92; 95% CI: 3.35–18.74; p < 0.001) and donor chimerism (CD3) in bone marrow at relapse (HR = 1.02; 95% CI: 1.00–1.03; p = 0.036) were independent factors affecting HLA loss relapse. The ratio of negative conversion of FLT3‐ITD or CEBPA mutation was significantly lower in patients with post‐transplantation HLA loss relapse than in the non‐HLA loss group (0.0% vs. 45.5%, p = 0.003; 0.0% vs. 80.0%, p = 0.035), with none of the patients with FLT3‐ITD or CEBPA mutation turned negative in the HLA loss group. The number of gene mutations turned negative when relapse in the non‐HLA loss group was remarkably higher than that in the HLA loss group (p = 0.001). Using donor lymphocyte infusion (DLI) could not prolong OS for the HLA loss group (p = 0.42). Nevertheless, second transplantation had a significant positive impact on OS in the HLA loss group (p = 0.017), although only five patients in the HLA loss group underwent second transplantation. However, patients in the non‐HLA loss group using DLI had a relatively longer OS time than those without DLI (p = 0.017). Second transplantation could also prolong OS in the non‐HLA loss group, but the effect was not as significant as in the HLA loss group (p = 0.053). In summary, HLA loss detection is essential for patients with recurrence after transplantation, especially for those with more HLA mismatched loci and non‐sibling donor. Furthermore, the detection of HLA loss has a guiding role in choosing subsequent therapy when relapsed, as secondary transplantation is more suitable than DLI for those with HLA loss.
- 7 February 2024
- Published by Wiley in British Journal of Haematology
- Vol. 204 (4) , 1402-1413
Risk factors and survival analysis of human leukocyte antigen loss in relapsed acute myeloid leukaemia/myelodysplastic syndrome patients after allogeneic haematopoietic stem cell transplantation
Summary: To investigate the clinical characteristics and risk factors of specific human leukocyte antigen loss (HLA loss) in relapsed acute myeloid leukaemia (AML)/myelodysplastic syndrome (MDS) patients after allogeneic haematopoietic stem cell transplantation (allo‐HSCT), and compare the responses of patients with HLA loss relapse with those without HLA loss (non‐HLA loss) to different treatment regimens. Clinical data of traceable patients with AML/MDS after myeloablative allo‐HSCT in our centre between January 2010 and June 2021, who experienced disease relapse after the transplantation, were collected. The patients were divided into the HLA loss relapse group and the non‐HLA loss relapsed group based on HLA loss gene test findings by next‐generation sequencing. The patients' median overall survival (OS) after the relapse were compared, and univariate and multivariate analyses were performed using the Kaplan–Meier survival curve and Cox proportional hazard model to explore the responses to different treatments after relapse. A total of 2359 patients were selected. Retrospective HLA gene loss gene detection was performed for the deoxyribonucleic acid in 179 relapsed patients, including 47 patients in the HLA loss group (27.2%), 126 patients in the non‐HLA loss group (72.8%) and 6 patients were excluded due to a lack of confirmed results. There was no significant statistical difference in the baseline characteristics of patients between the two groups, but as to transplantation‐related characteristics, the donor–recipient relationship and HLA mismatched loci were statistically different between the two groups (both p < 0.001). Multivariate Cox analysis showed that more HLA mismatched loci ≥3 (HR = 3.66; 95% CI: 1.61–8.31; p = 0.002), time (≤6 months) from HSCT to relapse (HR = 7.92; 95% CI: 3.35–18.74; p < 0.001) and donor chimerism (CD3) in bone marrow at relapse (HR = 1.02; 95% CI: 1.00–1.03; p = 0.036) were independent factors affecting HLA loss relapse. The ratio of negative conversion of FLT3‐ITD or CEBPA mutation was significantly lower in patients with post‐transplantation HLA loss relapse than in the non‐HLA loss group (0.0% vs. 45.5%, p = 0.003; 0.0% vs. 80.0%, p = 0.035), with none of the patients with FLT3‐ITD or CEBPA mutation turned negative in the HLA loss group. The number of gene mutations turned negative when relapse in the non‐HLA loss group was remarkably higher than that in the HLA loss group (p = 0.001). Using donor lymphocyte infusion (DLI) could not prolong OS for the HLA loss group (p = 0.42). Nevertheless, second transplantation had a significant positive impact on OS in the HLA loss group (p = 0.017), although only five patients in the HLA loss group underwent second transplantation. However, patients in the non‐HLA loss group using DLI had a relatively longer OS time than those without DLI (p = 0.017). Second transplantation could also prolong OS in the non‐HLA loss group, but the effect was not as significant as in the HLA loss group (p = 0.053). In summary, HLA loss detection is essential for patients with recurrence after transplantation, especially for those with more HLA mismatched loci and non‐sibling donor. Furthermore, the detection of HLA loss has a guiding role in choosing subsequent therapy when relapsed, as secondary transplantation is more suitable than DLI for those with HLA loss.
- Open Access
- 5 February 2024
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 28 (3) , e18114
The novel TERF2::PDGFRB fusion gene enhances tumorigenesis via PDGFRB/STAT5 signalling pathways and sensitivity to TKI in ph‐like ALL
Patients with Philadelphia chromosome‐like acute lymphoblastic leukaemia (Ph‐like ALL) often face a grim prognosis, with PDGFRB gene fusions being commonly detected in this subgroup. Our study has unveiled a newfound fusion gene, TERF2::PDGFRB, and we have found that patients carrying this fusion gene exhibit sensitivity to dasatinib. Ba/F3 cells harbouring the TERF2::PDGFRB fusion display IL‐3‐independent cell proliferation through activation of the p‐PDGFRB and p‐STAT5 signalling pathways. These cells exhibit reduced apoptosis and demonstrate sensitivity to imatinib in vitro. When transfused into mice, Ba/F3 cells with the TERF2::PDGFRB fusion gene induce tumorigenesis and a shortened lifespan in cell‐derived graft models, but this outcome can be improved with imatinib treatment. In summary, we have identified the novel TERF2::PDGFRB fusion gene, which exhibits oncogenic potential both in vitro and in vivo, making it a potential therapeutic target for tyrosine kinase inhibitors (TKIs).
- 5 February 2024
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 28 (3) , e18114
Open AccessThe novel TERF2::PDGFRB fusion gene enhances tumorigenesis via PDGFRB/STAT5 signalling pathways and sensitivity to TKI in ph‐like ALL
Patients with Philadelphia chromosome‐like acute lymphoblastic leukaemia (Ph‐like ALL) often face a grim prognosis, with PDGFRB gene fusions being commonly detected in this subgroup. Our study has unveiled a newfound fusion gene, TERF2::PDGFRB, and we have found that patients carrying this fusion gene exhibit sensitivity to dasatinib. Ba/F3 cells harbouring the TERF2::PDGFRB fusion display IL‐3‐independent cell proliferation through activation of the p‐PDGFRB and p‐STAT5 signalling pathways. These cells exhibit reduced apoptosis and demonstrate sensitivity to imatinib in vitro. When transfused into mice, Ba/F3 cells with the TERF2::PDGFRB fusion gene induce tumorigenesis and a shortened lifespan in cell‐derived graft models, but this outcome can be improved with imatinib treatment. In summary, we have identified the novel TERF2::PDGFRB fusion gene, which exhibits oncogenic potential both in vitro and in vivo, making it a potential therapeutic target for tyrosine kinase inhibitors (TKIs).
- Open Access
- 30 November 2023
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 13, 1302356
Identification of a venetoclax-resistance prognostic signature base on 6-senescence genes and its clinical significance for acute myeloid leukemia
Background: Satisfactory responses can be obtained for acute myeloid leukemia (AML) treated by Venetoclax (VEN)-based therapy. However, there are still quite a few AML patients (AMLs) resistant to VEN, and it is critical to understand whether VEN-resistance is regulated by senescence.Methods: Here, we established and validated a signature for predicting AML prognosis based on VEN resistance-related senescence genes (VRSGs). In this study, 51 senescence genes were identified with VEN-resistance in AML. Using LASSO algorithms and multiple AML cohorts, a VEN-resistance senescence prognostic model (VRSP-M) was developed and validated based on 6-senescence genes.Results: According to the median score of the signature, AMLs were classified into two subtypes. A worse prognosis and more adverse features occurred in the high-risk subtype, including older patients, non-de novo AML, poor cytogenetics, adverse risk of European LeukemiaNet (ELN) 2017 recommendation, and TP53 mutation. Patients in the high-risk subtype were mainly involved in monocyte differentiation, senescence, NADPH oxidases, and PD1 signaling pathway. The model’s risk score was significantly associated with VEN-resistance, immune features, and immunotherapy response in AML. In vitro, the IC50 values of ABT-199 (VEN) rose progressively with increasing expression of G6PD and BAG3 in AML cell lines.Conclusions: The 6-senescence genes prognostic model has significant meaning for the prediction of VEN-resistance, guiding personalized molecularly targeted therapies, and improving AML prognosis.
- 30 November 2023
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 13, 1302356
Open AccessIdentification of a venetoclax-resistance prognostic signature base on 6-senescence genes and its clinical significance for acute myeloid leukemia
Background: Satisfactory responses can be obtained for acute myeloid leukemia (AML) treated by Venetoclax (VEN)-based therapy. However, there are still quite a few AML patients (AMLs) resistant to VEN, and it is critical to understand whether VEN-resistance is regulated by senescence.Methods: Here, we established and validated a signature for predicting AML prognosis based on VEN resistance-related senescence genes (VRSGs). In this study, 51 senescence genes were identified with VEN-resistance in AML. Using LASSO algorithms and multiple AML cohorts, a VEN-resistance senescence prognostic model (VRSP-M) was developed and validated based on 6-senescence genes.Results: According to the median score of the signature, AMLs were classified into two subtypes. A worse prognosis and more adverse features occurred in the high-risk subtype, including older patients, non-de novo AML, poor cytogenetics, adverse risk of European LeukemiaNet (ELN) 2017 recommendation, and TP53 mutation. Patients in the high-risk subtype were mainly involved in monocyte differentiation, senescence, NADPH oxidases, and PD1 signaling pathway. The model’s risk score was significantly associated with VEN-resistance, immune features, and immunotherapy response in AML. In vitro, the IC50 values of ABT-199 (VEN) rose progressively with increasing expression of G6PD and BAG3 in AML cell lines.Conclusions: The 6-senescence genes prognostic model has significant meaning for the prediction of VEN-resistance, guiding personalized molecularly targeted therapies, and improving AML prognosis.
- 27 November 2023
- Published by Wiley in British Journal of Haematology
- Vol. 204 (3) , 1100-1104
Single‐cell RNA ‐seq reveals the links between the metabolic heterogeneity and cell identity in NBM and AML
- 27 November 2023
- Published by Wiley in British Journal of Haematology
- Vol. 204 (3) , 1100-1104
Single‐cell RNA ‐seq reveals the links between the metabolic heterogeneity and cell identity in NBM and AML
- Open Access
- 26 April 2022
- Published by Taylor & Francis in Hematology
- Vol. 27 (1) , 499-505
Prognostic impact of PRDM16 expression in acute myeloid leukemia with normal cytogenetics
Cytogenetically normal acute myeloid leukemia (CN-AML) is a heterogeneous disease with variable clinical outcomes. The identification of potential biomarkers to better classify the patients with un...
- 26 April 2022
- Published by Taylor & Francis in Hematology
- Vol. 27 (1) , 499-505
Open AccessPrognostic impact of PRDM16 expression in acute myeloid leukemia with normal cytogenetics
Cytogenetically normal acute myeloid leukemia (CN-AML) is a heterogeneous disease with variable clinical outcomes. The identification of potential biomarkers to better classify the patients with un...
- Open Access
- 11 May 2021
- Published by Taylor & Francis in Autoimmunity
- Vol. 54 (5) , 294-302
Sema4D correlates with tumour immune infiltration and is a prognostic biomarker in bladder cancer, renal clear cell carcinoma, melanoma and thymoma
Sema4D, a member of the immune semaphorin family, plays crucial roles in the immune regulation, bone resorption and nervous system. It is also involved in angiogenesis and tumour progression. However, systemic studies on the correlation between Sema4D expression and the immune infiltration or clinical outcomes in tumours are still limited. Here, we analysed the landscape of Sema4D expression and its prognostic value in the cancer genome atlas pan-cancer as well as the correlation between Sema4D and immune cell infiltration by Tumour Immune Estimation Resource and Gene Expression Profiling interactive analysis online tools. Results showed that a higher Sema4D expression was significantly correlated with a favourable overall survival in diverse solid tumours including bladder cancer (Hazards Ratio (HR)=0.68, p = .0095), kidney renal clear cell carcinoma (HR = 0.61, p = .0016), melanoma (HR = 0.58, p = 6.6e-05) and thymoma (HR = 0.1, p = .011). Interestingly, Sema4D expression has positive correlation with various tumour infiltrating immune cells and immune cell biomarkers in these tumours. These results suggest that Sema4D could be a prospective biomarker for calculating hazard ratio of tumour patients and their tumour immune infiltration levels.
- 11 May 2021
- Published by Taylor & Francis in Autoimmunity
- Vol. 54 (5) , 294-302
Open AccessSema4D correlates with tumour immune infiltration and is a prognostic biomarker in bladder cancer, renal clear cell carcinoma, melanoma and thymoma
Sema4D, a member of the immune semaphorin family, plays crucial roles in the immune regulation, bone resorption and nervous system. It is also involved in angiogenesis and tumour progression. However, systemic studies on the correlation between Sema4D expression and the immune infiltration or clinical outcomes in tumours are still limited. Here, we analysed the landscape of Sema4D expression and its prognostic value in the cancer genome atlas pan-cancer as well as the correlation between Sema4D and immune cell infiltration by Tumour Immune Estimation Resource and Gene Expression Profiling interactive analysis online tools. Results showed that a higher Sema4D expression was significantly correlated with a favourable overall survival in diverse solid tumours including bladder cancer (Hazards Ratio (HR)=0.68, p = .0095), kidney renal clear cell carcinoma (HR = 0.61, p = .0016), melanoma (HR = 0.58, p = 6.6e-05) and thymoma (HR = 0.1, p = .011). Interestingly, Sema4D expression has positive correlation with various tumour infiltrating immune cells and immune cell biomarkers in these tumours. These results suggest that Sema4D could be a prospective biomarker for calculating hazard ratio of tumour patients and their tumour immune infiltration levels.